Immunome
Latest round
- Series A
Last raised
- Jun 2020
Total raised
- $11M
Investors
- 1
About Immunome
a. Immunome operates as a biotechnology company that develops novel antibody-based therapeutics by unlocking the human memory B cell response. In February 2024, Immunome Inc. Immunome focuses on developing targeted therapies for oncology. The company’s work includes creating advanced treatments that specifically target cancer cells. Immunome’s approach involves leveraging cutting-edge technology and scientific research to develop these specialized therapies.
Who invested in Immunome
1 investor across 3 rounds
See all investors in Immunome
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Immunome
Who invested in Immunome?
Immunome has 1 investor on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Immunome raised?
Immunome has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Immunome last raise money?
Immunome's most recent round on record is a Series A, in Jun 2020.
What does Immunome do?
Immunome is a biotechnology company.
Where is Immunome headquartered?
Immunome is headquartered in Bothell, US.
Which VCs invest in companies like Immunome?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Immunome's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Immunome? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.